#BEGIN_DRUGCARD DB01167

# AHFS_Codes:
08:14.08

# ATC_Codes:
J02AC02

# Absorption:
The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.

# Biotransformation:
Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.

# Brand_Mixtures:
Not Available

# Brand_Names:
Hyphanox
Itrizole
Oriconazole
Sporal
Sporanos
Sporanox
Sporonox
Triasporn

# CAS_Registry_Number:
84625-61-6

# ChEBI_ID:
6076

# Chemical_Formula:
C35H38Cl2N8O4

# Chemical_IUPAC_Name:
1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2231347

# Description:
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis.  It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis. [PubChem]

# Dosage_Forms:
Capsule	Oral
Liquid	Oral

# Drug_Category:
Antifungal Agents
Antifungals
Antiprotozoal Agents
Antiprotozoals

# Drug_Interactions:
Abiraterone 	Strong CYP3A4 inhibitors may increase levels of abiraterone. Monitor concomitant therapy closely.
Acenocoumarol	Itraconazole may increase the anticoagulant effect of acenocoumarol.
Alfentanil	Itraconazole may increase the effect and toxicity of alfentanil.
Alfuzosin	The antifungal increases the effect of alfuzosin
Almotriptan	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
Alprazolam	Itraconazole may increase the effect of the benzodiazepine, alprazolam.
Aluminium	Aluminum-containing antacids may decrease the effect of itraconazole.
Anisindione	Itraconazole may increase the anticoagulant effect of anisindione.
Apixaban	Avoid combination. Otherwise, itraconazole will likely increase apixaban serum concentration.
Aprepitant	This CYP3A4 inhibitor, itraconazole, may increase the effect and toxicity of aprepitant.
Aripiprazole	Itraconazole may increase the effect of aripiprazole.
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Atorvastatin	Increased risk of myopathy/rhabdomyolysis
Bosentan	Itraconazole may increase the effect and toxicity of bosentan.
Bromazepam	Itraconazole may increase the serum concentration of bromazepam by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bromazepam if itraconazole is initiated, discontinued or dose changed.
Budesonide	Itraconazole may increase levels/effect of budesonide.
Cabazitaxel	Concomitant therapy with a strong CYP3A4 inhibitor may increase concentrations of cabazitaxel. Avoid concomitant therapy.
Calcium	Calcium-containing antacids may decrease the effect of itraconazole.
Calcium carbonate	The antacid, calcium carbonate, may decrease the effect of itraconazole by decreasing its absorption.
Carbamazepine	Itraconazole may increase the effect of carbamazepine.
Celiprolol	Itaconazole increases levels/effect of celiprolol
Cerivastatin	Increased risk of myopathy/rhabdomyolysis
Chlordiazepoxide	Itraconazole may increase the effect of the benzodiazepine, chlordiazepoxide.
Ciclesonide	Increased effects/toxicity of ciclesonide
Cilostazol	Itraconazole may increase the effect of cilostazol.
Cimetidine	The H2-receptor antagonist, cimetidine, may decrease the absorption of itraconazole.
Cinacalcet	Itraconazole may increase the effect and toxicity of cinacalcet.
Cisapride	Increased risk of cardiotoxicity and arrhythmias
Clarithromycin	The macrolide, clarithromycin, may increase the effect and toxicity of itraconazole.
Clonazepam	Itraconazole may increase the effect of the benzodiazepine, clonazepam.
Clorazepate	Itraconazole may increase the effect of the benzodiazepine, clorazepate.
Conivaptan	Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan. Concomitant use of conivaptan with strong CYP3A4 inhibitors (e.g., azole antifungals) is contraindicated.
Cyclosporine	Itraconazole may increase the effect of cyclosporine.
Dantrolene	Itraconazole may increase the serum concentration of dantrolene by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of dantrolene if itraconazole is initiated, discontinued or dose changed.
Darifenacin	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
Diazepam	Itraconazole may increase the effect of the benzodiazepine, diazepam.
Dicumarol	Itraconazole may increase the anticoagulant effect of dicumarol.
Digoxin	Itraconazole increases the effect of digoxin
Dihydroergotamine	Possible ergotism and severe ischemia with this combination
Dofetilide	This strong CYP3A4 inhibitor increases the effect and toxicity of dofetilide
Dronedarone	Itraconazole is a strong CYP3A4 inhibitor in which concomitant use with dronedarone will significantly increase its exposure. Avoid concomitant use.
Eletriptan	This potent CYP3A4 inhibitor increases the effect and toxicity of the triptan
Eplerenone	Itraconazole may increase the effect and toxicity of eplerenone.
Ergotamine	Possible ergotism and severe ischemia with this combination
Erlotinib	Itraconazole may decrease the metabolism of erlotinib. Monitor for changes in the therapeutic and adverse effects of erlotinib if itraconazole is initiated, discontinued or dose changed.
Erythromycin	The macrolide, erythromycin, may increase the effect and toxicity of itraconazole.
Esomeprazole	The proton pump inhibitor, esomeprazole, may decrease the absorption of itraconazole.
Estazolam	Itraconazole may increase the effect of the benzodiazepine, estazolam.
Ethotoin	Phenytoin decreases the effect of itraconazole
Everolimus	Itraconazole may increase everolimus levels/toxicity.
Famotidine	The H2-receptor antagonist, famotidine, may decrease the absorption of itraconazole.
Felodipine	Itraconazole may increase the therapeutic and adverse effects of felodipine.
Fentanyl	Itraconazole may increase levels/toxicity of fentanyl.
Flurazepam	Itraconazole may increase the effect of the benzodiazepine, flurazepam.
Fosphenytoin	Phenytoin decreases the effect of itraconazole
Gefitinib	Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of gefitinib. Monitor for changes in the therapeutic and adverse effects of gefitinib if itraconazole is initiated, discontinued or dose changed.
Halazepam	Itraconazole may increase the effect of the benzodiazepine, halazepam.
Haloperidol	Itraconazole may increase the effect and toxicity of haloperidol.
Imatinib	Itraconazole may increase the levels of imatinib.
Ivacaftor	Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely.
Josamycin	The macrolide, josamycin, may increase the effect and toxicity of itraconazole.
Lansoprazole	The proton pump inhibitor, lansoprazole, may decrease the absorption of itraconazole.
Levomethadyl Acetate	Itraconazole increases the effect/toxicity of levomethadyl
Lovastatin	Increased risk of myopathy/rhabdomyolysis
Lurasidone	Concomitant therapy with a strong CYP3A4 inhibitor will increase level or effect of lurasidone. Coadministration with lurasidone is contraindicated.
Magnesium oxide	The antacid, magnesium oxide, may decrease the effect of itraconazole by decreasing its absorption.
Mephenytoin	Phenytoin decreases the effect of itraconazole
Mestranol	This anti-infectious agent could decrease the effect of the oral contraceptive
Methylprednisolone	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, methylprednisolone.
Midazolam	Itraconazole may increase the effect of the benzodiazepine, midazolam.
Nizatidine	The H2-receptor antagonist, nizatidine, may decrease the absorption of itraconazole.
Omeprazole	The proton pump inhibitor, omeprazole, may decrease the absorption of itraconazole.
Pantoprazole	The proton pump inhibitor, pantoprazole, may decrease the absorption of itraconazole.
Pazopanib	Affects CYP3A4 metabolism therefore will decrease levels or effect of pazopanib. Consider alternate therapy.
Phenobarbital	The barbiturate, phenobarbital, decreases the effect of itraconazole.
Phenytoin	Phenytoin decreases the effect of itraconazole
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Ponatinib 	Strong CYP3A4 inhibitors may increase levels of ponatinib. Monitor concomitant therapy closely.
Prednisolone	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisolone.
Prednisone	The imidazole, itraconazole, may increase the effect and toxicity of the corticosteroid, prednisone.
Quazepam	Itraconazole may increase the effect of the benzodiazepine, quazepam.
Quinidine	Itraconazole may increase the effect and toxicity of quinidine.
Quinidine barbiturate	Itraconazole may increase the effect and toxicity of quinidine barbiturate.
Rabeprazole	The proton pump inhibitor, rabeprazole, may decrease the absorption of itraconazole.
Ranitidine	The H2-receptor antagonist, ranitidine, may decrease the absorption of itraconazole.
Ranolazine	Increased levels of ranolazine - risk of toxicity
Regorafenib	Strong CYP3A4 inhibitors may increase levels of regorafenib.
Rifabutin	Rifabutin decreases the effect of itraconazole
Rifampin	Rifampin may decrease the effect of itraconazole.
Risperidone	Increases the level of risperidone
Ritonavir	Itraconazole may increase the effect and toxicity of ritonavir.
Rivaroxaban	Use of rivaroxaban with agents that are strong inhibitors of both CYP3A4 and P-glycoproteins are contraindicated.
Ruxolitinib	Strong CYP3A4 inhibitors may increase levels of ruxolitinib. Consider alternate therapy.
Sildenafil	Itraconazole may increase the effect and toxicity of sildenafil.
Silodosin	Strong CYP3A4 inhibitors may increase levels of silodosin. Concomitant administration is contraindicated.
Simvastatin	Increased risk of myopathy/rhabdomyolysis
Sirolimus	Itraconazole may increase the effect and toxicity of sirolimus.
Solifenacin	This potent CYP3A4 inhibitor slows darifenacin/solifenacin metabolism
Sucralfate	Sucralfate may decrease the absorption of itraconazole.
Sunitinib	Possible increase in sunitinib levels
Tacrolimus	The antifungal, Itraconazole, may increase serum concentrations of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Itraconazole therapy is initiated, discontinued or altered.
Tadalafil	Itraconazole may reduce the metabolism of Tadalafil. Concomitant therapy should be avoided if possible due to high risk of Tadalafil toxicity.
Tamoxifen	Itraconazole may increase the serum concentration of Tamoxifen by decreasing its metabolism. Monitor for increased adverse/toxic effects of Tamoxifen.
Tamsulosin	Itraconazole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Itraconazole is initiated, discontinued, or dose changed.
Telithromycin	Itraconazole may increase the plasma concentration of Telithromycin. Consider alternate therapy or monitor therapeutic/adverse effects.
Temsirolimus	Itraconazole may inhibit the metabolism and clearance of Temsirolimus. Concomitant therapy should be avoided.
Teniposide	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Teniposide, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Teniposide if Itraconazole is initiated, discontinued or dose changed.
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Tiagabine	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Tiagabine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Tiagabine if Itraconazole is initiated, discontinued or dose changed.
Tipranavir	Tipranavir may increase the serum concentration of Itraconazole.
Tolterodine	Itraconazole may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity.
Tolvaptan	Itraconazole is a strong inhibitor of CYP3A4 and will increase serum concentrations of tolvaptan.
Topotecan	The p-glycoprotein inhibitor, Itraconazole, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided.
Tramadol	Itraconazole may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance.
Trazodone	The CYP3A4 inhibitor, Itraconazole, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Consider alternate therapy or monitor for changes in Trazodone efficacy/toxicity if Itraconazole is initiated, discontinued or dose changed.
Triazolam	Itraconazole may increase the effect of the benzodiazepine, triazolam.
Trimipramine	The strong CYP3A4 inhibitor, Itraconazole, may decrease the metabolism and clearance of Trimipramine, a CYP3A4 substrate. Consider alternate therapy or monitor for changes in therapeutic and adverse effects of Trimipramine if Itraconazole is initiated, discontinued or dose changed.
Ulipristal 	Concomitant therapy with strong CYP3A4 inhibitors may increase plasma concentrations of ulipristal. Avoid combination therapy.
Vardenafil	Itraconazole, a potent CYP3A4 inhibitor, may decrease the metabolism and clearance of Vardenafil. Concomitant therapy is contraindicated.
Vemurafenib	Strong CYP3A4 inhibitors may increase levels of vemurafenib. Monitor concomitant therapy closely.
Venlafaxine	Itraconaole, a CYP3A4 inhibitor, may decrease the metabolism and clearance of Venlafaxine, a CYP3A4 substrate. Monitor for changes in therapeutic/adverse effects of Venlafaxine if Itraconazole is initiated, discontinued, or dose changed.
Verapamil	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of Veramapil, a CYP3A4 substrate, by decreasing its metabolism and clearance. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Verapamil if Itraconazole is initiated, discontinued or dose changed.
Vinblastine	Itraconazole, a strong CYP3A4 inhibitor, may decrease the metabolism of Vinblastine. Consider alternate therapy to avoid Vinblastine toxicity. Monitor for changes in the therapeutic/adverse effects of Vinblastine if Itraconazole is initiated, discontinued or dose changed.
Vincristine	Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vincristine by decreasing its metabolism and/or increasing efflux. Consider alternate therapy to avoid Vincristine toxicity. Monitor for changes in the therapeutic and adverse effects of Vincristine if Itraconazole is initiated, discontinued or dose changed.
Vinorelbine	Itraconazole, a strong CYP3A4 and p-glycoprotein inhibitor, may increase the serum concentration of Vinorelbine by decreasing its metabolism and/or increasing its efflux. Consider alternate therapy to avoid Vinorelbine toxicity. Monitor for changes in the therapeutic and adverse effects of Vinorelbine if Itraconazole is initiated, discontinued or dose changed.
Warfarin	Itraconazole may increase the anticoagulant effect of warfarin by decreasing its metabolism.
Zolpidem	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zolpidem by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zolpidem if itraconazole is initiated, discontinued or dose changed.
Zonisamide	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zonisamide by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zonisamide if itraconazole is initiated, discontinued or dose changed.
Zopiclone	Itraconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of zopiclone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zopiclone if itraconzole is initiated, discontinued or dose changed.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
5.66

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Insoluble

# Food_Interactions:
Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
Avoid taking with grapefruit juice.
Take after a full meal.
Take with food.

# GenBank_ID:
Not Available

# Generic_Name:
Itraconazole

# HET_ID:
Not Available

# Half_Life:
21 hours

# InChI_Identifier:
InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1

# InChI_Key:
InChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N

# Indication:
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D00350

# LIMS_Drug_ID:
1167

# Mechanism_Of_Action:
Itraconazole interacts with 14-&alpha; demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

# Melting_Point:
166.2 Â°C

# Molecular_Weight_Avg:
705.633

# Molecular_Weight_Mono:
704.239307158

# Organisms_Affected:
Fungi, yeast and protozoans

# PDB_Experimental_ID:
1TQN

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/spo1411.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA450132

# Pharmacology:
Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 &alpha;-demethylation via the inhibition of the enzyme cytochrome P450 14&alpha;-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 &alpha;-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits <i>in vitro</i> activity against <i>Cryptococcus neoformans</i> and <i>Candida spp.</i> Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to <i>Cryptococcus neoformans</i> and for systemic infections due to <i>Candida albicans</i>.

# Predicted_LogP_Hydrophobicity:
5.48

# Predicted_LogS:
-4.9

# Predicted_Water_Solubility:
9.64e-03 g/l

# Primary_Accession_No:
DB01167

# Protein_Binding:
99.8%

# PubChem_Compound_ID:
55283

# PubChem_Substance_ID:
46505954

# RxList_Link:
http://www.rxlist.com/cgi/generic/itraconazole.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00040

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
ITC
ITCZ
ITZ
Itraconazol [Spanish]
Itraconazolum [Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.

# Update_Date:
2013-02-08 16:19:58 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Itraconazole

# pKa_Isoelectric_Point:
3.70

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A5

# Phase_1_Metabolizing_Enzyme_1_ID:
4118

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A5

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P20815

# Phase_1_Metabolizing_Enzyme_2_Gene_Name:
CYP2D6

# Phase_1_Metabolizing_Enzyme_2_ID:
4119

# Phase_1_Metabolizing_Enzyme_2_Name:
Cytochrome P450 2D6

# Phase_1_Metabolizing_Enzyme_2_Protein_Sequence:
>Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR

# Phase_1_Metabolizing_Enzyme_2_SwissProt_ID:
P10635

# Phase_1_Metabolizing_Enzyme_3_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_3_ID:
4512

# Phase_1_Metabolizing_Enzyme_3_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_3_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_3_SwissProt_ID:
P08684

# Phase_1_Metabolizing_Enzyme_4_Gene_Name:
CYP2E1

# Phase_1_Metabolizing_Enzyme_4_ID:
6013

# Phase_1_Metabolizing_Enzyme_4_Name:
Cytochrome P450 2E1

# Phase_1_Metabolizing_Enzyme_4_Protein_Sequence:
>Cytochrome P450 2E1
MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRL
AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP
TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI
ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA
EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG
TETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRF
ITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFPDPEKFKPEHFLNENGK
FKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGC
IPPRYKLCVIPRS

# Phase_1_Metabolizing_Enzyme_4_SwissProt_ID:
P05181

# Phase_1_Metabolizing_Enzyme_5_Gene_Name:
CYP1A1

# Phase_1_Metabolizing_Enzyme_5_ID:
6024

# Phase_1_Metabolizing_Enzyme_5_Name:
Cytochrome P450 1A1

# Phase_1_Metabolizing_Enzyme_5_Protein_Sequence:
>Cytochrome P450 1A1
MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPH
LALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQS
MSFSPDSGPVWAARRRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAG
PGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPIL
RYLPNPSLNAFKDLNEKFYSFMQKMVKEHYKTFEKGHIRDITDSLIEHCQEKQLDENANV
QLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLS
DRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRCVFVNQWQINHDQKL
WVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEF
SVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS

# Phase_1_Metabolizing_Enzyme_5_SwissProt_ID:
P04798

# Phase_1_Metabolizing_Enzyme_6_Gene_Name:
CYP2B6

# Phase_1_Metabolizing_Enzyme_6_ID:
6030

# Phase_1_Metabolizing_Enzyme_6_Name:
Cytochrome P450 2B6

# Phase_1_Metabolizing_Enzyme_6_Protein_Sequence:
>Cytochrome P450 2B6
MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFRE
KYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNR
WKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIIC
SIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQE
INAYIGHSVEKHRETLDPSAPKDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGT
ETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFS
DLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGAL
KKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKI
PPTYQIRFLPR

# Phase_1_Metabolizing_Enzyme_6_SwissProt_ID:
P20813

# Phase_1_Metabolizing_Enzyme_7_Gene_Name:
CYP3A7

# Phase_1_Metabolizing_Enzyme_7_ID:
6107

# Phase_1_Metabolizing_Enzyme_7_Name:
Cytochrome P450 3A7

# Phase_1_Metabolizing_Enzyme_7_Protein_Sequence:
>Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA

# Phase_1_Metabolizing_Enzyme_7_SwissProt_ID:
P24462

# Drug_Target_1_Cellular_Location:
Microsome (Potential)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10608831	Cotrim PC, Garrity LK, Beverley SM: Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection. J Biol Chem. 1999 Dec 31;274(53):37723-30.
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
16964330	Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G: Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
CYP51A1

# Drug_Target_1_GenBank_ID_Gene:
U23942

# Drug_Target_1_GenBank_ID_Protein:
1698396

# Drug_Target_1_GeneCard_ID:
CYP51A1

# Drug_Target_1_Gene_Name:
CYP51A1

# Drug_Target_1_Gene_Sequence:
>1530 bp
ATGGCGGCGGCGGCTGGGATGCTGCTGCTGGGCTTGCTGCAGGCGGGTGGGTCGGTGCTG
GGCCAGGCGATGGAGAAGGTGACAGGCGGCAACCTCTTGTCCATGCTGCTGATCGCCTGC
GCCTTCACCCTCAGCCTGGTCTACCTGATCCGTCTGGCCGCCGGCCACCTGGTCCAGCTG
CCCGCAGGGGTGAAAAGTCCTCCATACATTTTCTCCCCAATTCCATTCCTTGGGCATGCC
ATAGCATTTGGGAAAAGTCCAATTGAATTTCTAGAAAATGCATATGAGAAGTATGGACCT
GTATTTAGTTTTACCATGGTAGGCAAGACATTTACTTACCTTCTGGGGAGTGATGCTGCT
GCACTGCTTTTTAATAGTAAAAATGAAGACCTGAATGCAGAAGATGTCTACAGTCGCCTG
ACAACACCTGTGTTTGGGAAGGGAGTTGCATACGATGTGCCTAATCCAGTTTTCTTGGAG
CAGAAGAAAATGTTAAAAAGTGGCCTTAACATAGCCCACTTTAAACAGCATGTTTCTATA
ATTGAAAAAGAAACAAAGGAATACTTTGAGAGTTGGGGAGAAAGTGGAGAAAAAAATGTG
TTTGAAGCTCTTTCTGAGCTCATAATTTTAACAGCTAGCCATTGTTTGCATGGAAAGGAA
ATCAGAAGTCAACTCAATGAAAAGGTAGCACAGCTGTATGCAGATTTGGATGGAGGTTTC
AGCCATGCAGCCTGGCTCTTACCAGGTTGGCTGCCTTTGCCTAGTTTCAGACGCAGGGAC
AGAGCTCATCGGGAAATCAAGGATATTTTCTATAAGGCAATCCAGAAACGCAGACAGTCT
CAAGAAAAAATTGATGACATTCTCCAAACTTTACTAGATGCTACATACAAGGATGGGCGT
CCTTTGACTGATGATGAAGTAGCAGGGATGCTTATTGGATTACTCTTGGCAGGGCAGCAT
ACATCCTCAACTACTAGTGCTTGGATGGGCTTCTTTTTGGCCAGAGACAAAACACTTCAA
AAAAAATGTTATTTAGAACAGAAAACAGTCTGTGGAGAGAATCTGCCTCCTTTAACTTAT
GACCAGCTCAAGGATCTAAATTTACTTGATCGCTGTATAAAAGAAACATTAAGACTTAGA
CCTCCTATAATGATCATGATGAGAATGGCCAGAACTCCTCAGACTGTGGCAGGGTATACC
ATTCCTCCAGGACATCAGGTGTGTGTTTCTCCCACTGTCAATCAAAGACTTAAAGACTCA
TGGGTAGAACGCCTGGACTTTAATCCTGATCGCTACTTACAGGATAACCCAGCATCAGGG
GAAAAGTTTGCCTATGTGCCATTTGGAGCTGGGCGTCATCGTTGTATTGGGGAAAATTTT
GCCTATGTTCAAATTAAGACAATTTGGTCCACTATGCTTCGTTTATATGAATTTGATCTC
ATTGATGGATACTTTCCCACTGTGAATTATACAACTATGATTCACACCCCTGAGAACCCA
GTTATCCGTTACAAACGAAGATCAAAATGA

# Drug_Target_1_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_1_General_References:
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
8619637	Stromstedt M, Rozman D, Waterman MR: The ubiquitously expressed human CYP51 encodes lanosterol 14 alpha-demethylase, a cytochrome P450 whose expression is regulated by oxysterols. Arch Biochem Biophys. 1996 May 1;329(1):73-81.
8809088	Rozman D, Stromstedt M, Waterman MR: The three human cytochrome P450 lanosterol 14 alpha-demethylase (CYP51) genes reside on chromosomes 3, 7, and 13: structure of the two retrotransposed pseudogenes, association with a line-1 element, and evolution of the human CYP51 family. Arch Biochem Biophys. 1996 Sep 15;333(2):466-74.
8975714	Rozman D, Stromstedt M, Tsui LC, Scherer SW, Waterman MR: Structure and mapping of the human lanosterol 14alpha-demethylase gene (CYP51) encoding the cytochrome P450 involved in cholesterol biosynthesis; comparison of exon/intron organization with other mammalian and fungal CYP genes. Genomics. 1996 Dec 15;38(3):371-81.

# Drug_Target_1_HGNC_ID:
HGNC:2649

# Drug_Target_1_HPRD_ID:
03381

# Drug_Target_1_ID:
1010

# Drug_Target_1_Locus:
7q21.2-q21.3

# Drug_Target_1_Molecular_Weight:
56807

# Drug_Target_1_Name:
Cytochrome P450 51A1

# Drug_Target_1_Number_of_Residues:
503

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_1_Protein_Sequence:
>Cytochrome P450 51A1
MLLLGLLQAGGSVLGQAMEKVTGGNLLSMLLIACAFTLSLVYLIRLAAGHLVQLPAGVKS
PPYIFSPIPFLGHAIAFGKSPIEFLENAYEKYGPVFSFTMVGKTFTYLLGSDAAALLFNS
KNEDLNAEDVYSRLTTPVFGKGVAYDVPNPVFLEQKKMLKSGLNIAHFKQHVSIIEKETK
EYFESWGESGEKNVFEALSELIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFSHAAWL
LPGWLPLPSFRRRDRAHREIKDIFYKAIQKRRQSQEKIDDILQTLLDATYKDGRPLTDDE
VAGMLIGLLLAGQHTSSTTSAWMGFFLARDKTLQKKCYLEQKTVCGENLPPLTYDQLKDL
NLLDRCIKETLRLRPPIMIMMRMARTPQTVAGYTIPPGHQVCVSPTVNQRLKDSWVERLD
FNPDRYLQDNPASGEKFAYVPFGAGRHRCIGENFAYVQIKTIWSTMLRLYEFDLIDGYFP
TVNYTTMIHTPENPVIRYKRRSK

# Drug_Target_1_Reaction:
obtusifoliol + 3 O2 + 3 NADPH + 3 H+ = 4alpha-methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol + formate + 3 NADP+ + 4 H2O

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol

# Drug_Target_1_SwissProt_ID:
Q16850

# Drug_Target_1_SwissProt_Name:
CP51A_HUMAN

# Drug_Target_1_Synonyms:
CYPLI
EC 1.14.13.70
LDM
Lanosterol 14-alpha demethylase
P450-14DM
P45014DM
P450LI
Sterol 14-alpha demethylase

# Drug_Target_1_Theoretical_pI:
8.72

# Drug_Target_1_Transmembrane_Regions:
24-44

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10991846	Henry KW, Nickels JT, Edlind TD: Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2000 Oct;44(10):2693-700.
12606318	Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr: Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol. 2003 Aug;29(2):232-8. Epub 2003 Feb 26.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9326581	Gachotte D, Pierson CA, Lees ND, Barbuch R, Koegel C, Bard M: A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11173-8.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
L40389

# Drug_Target_2_GenBank_ID_Protein:
755693

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ERG11

# Drug_Target_2_Gene_Sequence:
>1602 bp
ATGTCCACTGAAAACACTTCTTTGGTCGTTGAACTATTGGAGTACGTGAAGCTTGGTCTT
TCGTACTTCCAAGCTCTGCCATTGGCGCAGAGAGTGTCTATTATGGTCGCCTTGCCATTT
GTGTACACCATCACATGGCAATTGCTTTACTCCTTGAGAAAGGACAGACCACCACTTGTG
TTCTACTGGATCCCATGGGTCGGCTCTGCTATCCCATACGGTACCAAGCCATACGAGTTC
TTCGAAGACTGCCAAAAGAAATACGGTGATATCTTCTCTTTCATGCTATTGGGTAGAATT
ATGACTGTCTACTTGGGTCCAAAGGGTCACGAATTCATCTTCAACGCCAAGTTGGCCGAT
GTTTCCGCTGAAGCTGCTTACTCCCACTTGACCACCCCAGTGTTCGGTAAAGGTGTTATC
TACGATTGTCCAAACCACAGACTAATGGAACAAAAGAAGTTTGTCAAGGGTGCTTTGACT
AAGGAAGCCTTTGTCAGATACGTTCCATTGATCGCTGAGGAAATCTACAAGTACTTCAGA
AACTCCAAGAACTTCAAGATCAACGAAAACAACTCCGGTATCGTCGACGTTATGGTCTCC
CAACCTGAAATGACTATCTTCACTGCTTCCAGATCCTTGCTAGGTAAGGAAATGAGAGAC
AAGTTGGACACCGACTTCGCTTACTTGTACAGTGACTTGGACAAGGGTTTCACCCCAATT
AACTTCGTCTTCCCTAACTTGCCTCTAGAACACTACAGAAAGAGAGATCATGCCCAACAA
GCTATCTCTGGTACTTACATGTCCTTGATTAAGGAAAGACGTGAGAAGAACGATATCCAA
AACCGTGACTTGATTGATGAATTGATGAAGAACTCCACTTACAAGGATGGTACTAAGATG
ACCGACCAAGAAATTGCCAACCTATTGATTGGTGTCTTGATGGGTGGTCAACATACTTCC
GCTGCTACCTCCGCTTGGTGTCTATTGCATTTGGCTGAAAGACCAGATGTCCAAGAAGAA
TTATACCAAGAACAAATGCGCGTCTTGAACAACGATACCAAGGAATTGACTTACGATGAC
CTACAAAACATGCCTCTATTGAACCAAATGATCAAGGAAACTTTGAGATTGCACCACCCA
TTGCACTCTTTGTTCCGTAAAGTCATGAGAGATGTCGCTATTCCAAACACTTCCTACGTT
GTCCCAAGGGACTACCACGTTCTAGTCTCCCCAGGTTACACTCACTTGCAAGAAGAATTC
TTCCCTAAGCCAAATGAATTCAACATCCACCGTTGGGACGGTGATGCTGCTTCTTCCAGT
GCTGCTGGTGGTGACGAAGTTGATTACGGTTTCGGTGCTATCTCCAAGGGTGTTTCCTCT
CCATACTTGCCATTCGGTGGTGGTAGACACAGATGTATCGGTGAATTGTTCGCTTACTGT
CAATTGGGTGTGTTGATGTCCATTTTCATCAGAACCATGAAATGGCGTTACCCAACTGAA
GGTGAAACTGTCCCACCATCTGACTTCACCTCCATGGTCACCCTACCAACTGCCCCTGCT
AAGATCTACTGGGAAAAGAGACATCCAGAACAAAAGTACTAG

# Drug_Target_2_General_Function:
Secondary metabolites biosynthesis, transport and catabolism

# Drug_Target_2_General_References:
7989540	Burgener-Kairuz P, Zuber JP, Jaunin P, Buchman TG, Bille J, Rossier M: Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P-450 lanosterol-alpha-demethylase (L1A1) gene fragment. J Clin Microbiol. 1994 Aug;32(8):1902-7.
8593007	Geber A, Hitchcock CA, Swartz JE, Pullen FS, Marsden KE, Kwon-Chung KJ, Bennett JE: Deletion of the Candida glabrata ERG3 and ERG11 genes: effect on cell viability, cell growth, sterol composition, and antifungal susceptibility. Antimicrob Agents Chemother. 1995 Dec;39(12):2708-17.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
761

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
61306

# Drug_Target_2_Name:
Cytochrome P450 51

# Drug_Target_2_Number_of_Residues:
533

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00067	p450

# Drug_Target_2_Protein_Sequence:
>Cytochrome P450 51
MSTENTSLVVELLEYVKLGLSYFQALPLAQRVSIMVALPFVYTITWQLLYSLRKDRPPLV
FYWIPWVGSAIPYGTKPYEFFEDCQKKYGDIFSFMLLGRIMTVYLGPKGHEFIFNAKLAD
VSAEAAYSHLTTPVFGKGVIYDCPNHRLMEQKKFVKGALTKEAFVRYVPLIAEEIYKYFR
NSKNFKINENNSGIVDVMVSQPEMTIFTASRSLLGKEMRDKLDTDFAYLYSDLDKGFTPI
NFVFPNLPLEHYRKRDHAQQAISGTYMSLIKERREKNDIQNRDLIDELMKNSTYKDGTKM
TDQEIANLLIGVLMGGQHTSAATSAWCLLHLAERPDVQEELYQEQMRVLNNDTKELTYDD
LQNMPLLNQMIKETLRLHHPLHSLFRKVMRDVAIPNTSYVVPRDYHVLVSPGYTHLQEEF
FPKPNEFNIHRWDGDAASSSAAGGDEVDYGFGAISKGVSSPYLPFGGGRHRCIGELFAYC
QLGVLMSIFIRTMKWRYPTEGETVPPSDFTSMVTLPTAPAKIYWEKRHPEQKY

# Drug_Target_2_Reaction:
obtusifoliol + 3 O2 + 3 NADPH + 3 H+ = 4alpha-methyl-5alpha-ergosta-8,14,24(28)-trien-3beta-ol + formate + 3 NADP+ + 4 H2O

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol

# Drug_Target_2_SwissProt_ID:
P50859

# Drug_Target_2_SwissProt_Name:
CP51_CANGA

# Drug_Target_2_Synonyms:
CYPLI
EC 1.14.13.70
Lanosterol 14-alpha demethylase
P450-14DM
P450-LIA1
Sterol 14- alpha-demethylase

# Drug_Target_2_Theoretical_pI:
7.07

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB01167
